Researchers in the U.K. have overthrown the orthodox view that childhood cancers have a low mutation burden, opening up new drug targets and opportunities for repurposing existing therapies. In particular, a high mutation rate is associated with a response to cancer immunotherapy. But although PD-1 checkpoint inhibitors are approved for treating pediatric cancers with a high level of microsatellite instability mutations, in general it is thought childhood tumors are not amenable to immunotherapy.
Kumquat Biosciences Inc. has disclosed son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12C mutant) interaction inhibitors reported to be useful for the treatment of cancer.
Archeus Technologies Inc. and the Wisconsin Alumni Research Foundation (WARF) have entered into a strategic collaboration to advance ART-101, a next-generation prostate-specific membrane antigen (PSMA)-targeting small molecule, into clinical development for prostate cancer.
Proteinqure Inc. has closed an $11 million series A financing round to support the initiation of the company’s first clinical trial for PQ-203, a first-in-class peptide-drug conjugate for triple-negative breast cancer (TNBC). The funds will also be used to advance additional pipeline programs in neurology and nephrology.
Epimab Biotherapeutics Inc. licensed out a development-ready KLK2/CD3 bispecific T-cell engager (TCE) for advanced prostate cancer to Juri Biosciences Inc. through a potential $210 million deal.
Monte Rosa Therapeutics Inc. has divulged molecular glues as cyclin-dependent kinase 2 (CDK2) degradation inducers reported to be useful for the treatment of cancer and amyloidosis.
University of Michigan has disclosed prodrugs of stimulator of interferon genes protein (STING; TMEM173) agonists reported to be useful for the treatment of cancer, autoimmune disease, inflammatory disorder and infections.
Cell division cycle 20 homolog (CDC20) is a key regulatory protein involved in mitotic progression. Aberrant overexpression of CDC20 has been implicated in tumorigenesis and is associated with poor prognosis in several cancers, including triple-negative breast cancer.
Hepatocellular carcinoma (HCC) is a fatal cancer and the third cause of cancer-related deaths worldwide. Current therapies have focused on CAR T cells for treating HCC. Glypican-3 (GPC3) is a membrane protein that is overexpressed in HCC but not in healthy adult liver tissue, thus becoming a promising therapeutic target for HCC management.
Cholangiocarcinoma is a rare cancer that arises from the intrahepatic biliary epithelium or extrahepatic bile ducts. Apart from genetic mutations, epigenetic changes are also contributing to cancer development, making DNA methylation and histone modification focus for cancer research.
RSS
